The Hybridoma Library/Monoclonal Antibody Production Shared Resource develops new monoclonal antibodies and provides NCCC investigators with quality-controlled monoclonal antibodies (mAbs) as purified proteins and/or supernatants from hybridoma cell lines that have been obtained from the ATCC or from individual investigators. This facility maintains characterized and quality-controlled stocks of supernatants and monoclonal antibodies from over 100 cell lines. It is especially cost-effective for studies that require only a small sample of a given antibody that, purchased commercially, would result in a charge to individual grants of $250 to $500 per antibody. This Resource also advises investigators on the production and purification of large quantities of antibodies as needed. The Resource has recently been expanded to carry out hybridoma production for NCCC investigators. The entire procedure, beginning with animal immunizations and continuing up to and including subcloning of selected hybrids, is being carried out by the newly expanded facility. Individual investigators are currently being charged approximately one-third the cost of commercial production. Other services, such as in vitro antibody scale-up and purification, are being considered. During the past year, this Resource was used almost exclusively by NCCC investigators; in the case of previously existing antibodies, there previously was no charge-back system for supplying antibodies, which often come from patented cell lines. With the provision of a new service to produce monoclonal antibodies, for which there is a charge-back, it is estimated that the Resource will save investigators more than $200,000 per year over the commercial cost of comparable antibodies and services.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dartmouth College
United States
Zip Code
Rosenthal, Meredith B; Colla, Carrie H; Morden, Nancy E et al. (2018) Overuse and insurance plan type in a privately insured population. Am J Manag Care 24:140-146
Allaway, Robert J; Wood, Matthew D; Downey, Sondra L et al. (2018) Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells. Oncotarget 9:15860-15875
Soneji, Samir; Yang, JaeWon; Knutzen, Kristin E et al. (2018) Online Tobacco Marketing and Subsequent Tobacco Use. Pediatrics 141:
Everson, Todd M; Punshon, Tracy; Jackson, Brian P et al. (2018) Cadmium-Associated Differential Methylation throughout the Placental Genome: Epigenome-Wide Association Study of Two U.S. Birth Cohorts. Environ Health Perspect 126:017010
El-Jawahri, Areej; Fishman, Sarah R; Vanderklish, Julie et al. (2018) Pilot study of a multimodal intervention to enhance sexual function in survivors of hematopoietic stem cell transplantation. Cancer 124:2438-2446
Fricano-Kugler, Catherine J; Getz, Stephanie A; Williams, Michael R et al. (2018) Nuclear Excluded Autism-Associated Phosphatase and Tensin Homolog Mutations Dysregulate Neuronal Growth. Biol Psychiatry 84:265-277
Gacerez, Albert T; Sentman, Charles L (2018) T-bet promotes potent antitumor activity of CD4+ CAR T cells. Cancer Gene Ther 25:117-128
Yang, Wei; Schwartz, Gary N; Marotti, Jonathan D et al. (2018) Estrogen receptor alpha drives mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer. Oncotarget 9:8810-8822
Andrew, Angeline S; Chen, Celia Y; Caller, Tracie A et al. (2018) Toenail mercury Levels are associated with amyotrophic lateral sclerosis risk. Muscle Nerve :
Zhao, Yanding; Varn, Frederick S; Cai, Guoshuai et al. (2018) A P53-Deficiency Gene Signature Predicts Recurrence Risk of Patients with Early-Stage Lung Adenocarcinoma. Cancer Epidemiol Biomarkers Prev 27:86-95

Showing the most recent 10 out of 1911 publications